STAAR Surgical Company (STAA)
| Market Cap | 1.26B |
| Revenue (ttm) | 230.59M |
| Net Income (ttm) | -96.37M |
| Shares Out | 49.74M |
| EPS (ttm) | -1.95 |
| PE Ratio | n/a |
| Forward PE | 50.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 815,593 |
| Open | 26.84 |
| Previous Close | 26.60 |
| Day's Range | 25.36 - 26.87 |
| 52-Week Range | 13.50 - 30.81 |
| Beta | 1.01 |
| Analysts | Hold |
| Price Target | 22.50 (-11.35%) |
| Earnings Date | Nov 5, 2025 |
About STAA
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) and laser-based procedures, such as LASIK to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for STAA stock is "Hold." The 12-month stock price target is $22.5, which is a decrease of -11.35% from the latest price.
News
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms
California-based Palo Alto Investors sold 791,879 shares of STAAR Surgical Company in the third quarter, leading its position value to fall by $13.3 million. The transaction represented approximately ...
Broadwood Partners Working to Call Special Meeting of STAAR Surgical Shareholders to Remove Three Directors
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today announced that it is well along in the multi-step and time-consuming process that is required t...
Broadwood Partners Calls for the Appointment of New Directors at STAAR Surgical to Oversee Go-Shop Process
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today commented on the recent filing of amendments to the merger agreement in connection with the pro...
STAAR Surgical Announces Amendments to Alcon Merger Agreement
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Applauds STAAR Surgical's Strong Third Quarter Results and Reiterates That the Proposed Sale to Alcon Should Be Terminated.
STAAR Surgical Reports Third Quarter 2025 Results
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Condemns Alcon's Fallacious Attacks on STAAR Surgical and Its Prospects
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the investor presentation issued by Alcon Inc. (“Alcon”) (NYSE: ALC) regarding its propo...
Yunqi Capital Issues Letter to STAAR Surgical Board Calling for Termination of the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
STAAR Surgical Sets New Record Date and Postpones STAAR Special Meeting of Stockholders in Light of Ongoing Discussions with Alcon
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer® Lens (ICL) announced that, in light of ongoing discussions with Alcon (SIX/NY...
Yunqi Capital Issues Letter to STAAR Surgical Board Opposing Adjournment of the Special Meeting and Calling for the Company to Move Beyond the Proposed Merger with Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Condemns Decision by STAAR Surgical and Alcon to Delay Final Vote on Proposed Transaction
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NAS...
Alcon and STAAR Surgical Announce Adjournment of STAAR Special Meeting of Stockholders
GENEVA & LAKE FOREST, Calif.--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufact...
Staar Surgical's top investor calls shareholder meeting to remove directors
Medtech firm Staar Surgical's biggest investor, Broadwood Partners, is planning to call a shareholder meeting to remove several directors, it said on Wednesday, amid tensions over a proposed takeover ...
Broadwood Partners Intends to Call Special Meeting to Remove Several STAAR Surgical Directors
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which owns 27.5% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Company”) (NAS...
Yunqi Capital Issues Letter to STAAR Surgical's Board Calling for Timely Convening of the Special Meeting to Vote on the Alcon Transaction
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Broadwood Partners Highlights Growing Opposition to STAAR Surgical's Proposed Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the increasing public opposition to the proposed acquisition of STAAR Surgical Company (...
STAAR Surgical Announces Preliminary Net Sales Results for Third Quarter 2025
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Broadwood Partners Issues Letter to STAAR Surgical's Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory ...
Broadwood Partners Comments on STAAR Surgical's Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today commented on the recent Current Report on Form 8-K filed by STAAR Surgical Company (“STAAR” or the “C...
Broadwood Partners Issues Letter to STAAR Surgical's Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (...
STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading independent proxy advisory firm, ha...
Broadwood Partners Questions Integrity of STAAR Surgical's Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”) today sent the following letter to the shareholders of STAAR Surgical Company (“STAAR” or the “Company”) (N...